Sinecatechins is under clinical development by MediGene and currently in Phase III for Actinic (Solar) Keratosis. According to GlobalData, Phase III drugs for Actinic (Solar) Keratosis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sinecatechins’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sinecatechins overview
Sinecatechins (Veregen, Catephen) is an extract of green tea leaves from Camellia sinensis. It is formulated in the form of ointment for topical application. It is indicated for the topical treatment of actinic (solar) keratosis, external genital and perianal warts (condylomata acuminata) in immunocompetent patients 18 years and older. Veregen is under development for the treatment of basal cell carcinoma.
MediGene overview
MediGene is a biotechnology company. It is focused on developing T cell receptor (TCR)-guided therapies to combat cancer, leveraging natural T cell receptors combined with various immune components. The company’s End-to-End (E2E) Platform employs advanced technologies for TCR generation and optimization, enhancing the safety, efficacy, and durability of cell therapy products. MediGene‘s lead candidate, MDG1015, is a first-in-class TCR-T therapy targeting New York oesophageal squamous cell carcinoma 1/L Antigen Family Member-1a and co-expressing a PD1-41BB costimulatory switch protein, with upcoming clinical trials. It is also evaluating MDG2011, which targets the Kirsten rat sarcoma viral oncogene homologue G12V mutation. MediGene is headquartered in Planegg, Germany.
For a complete picture of Sinecatechins’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
